Delray Beach, FL, Aug. 11, 2025 (GLOBE NEWSWIRE) — The global cancer vaccines market is on track to nearly double over the next decade, climbing from USD 9.84 billion in 2024 to USD 15.00 billion by 2032 at a CAGR of 5.4%, according to MarketsandMarkets™. This translates into more than USD 10 billion in new market value over the next decade, creating significant opportunities for biopharma innovators, investors, and healthcare policy leaders.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30645011
Why is the market gaining momentum now?
The rapid rise in cancer incidence is prompting governments, healthcare providers, and industry leaders to prioritize prevention and targeted immunotherapy over reactive treatment models. Neoantigen-based cancer vaccines—personalized to a patient’s tumor profile—are driving a strategic shift in oncology, offering the potential for superior patient outcomes and reduced long-term treatment costs.
What types of vaccines lead—and where is the next growth wave?
The market is segmented into preventive and therapeutic vaccines. In 2023, preventive vaccines dominated due to global adoption of HPV vaccines (Gardasil, Cervarix) and Hepatitis B vaccines, both critical in reducing cervical and liver cancer risk.
The next growth wave lies in therapeutic cancer vaccines, such as Sipuleucel-T (Provenge) and pipeline neoantigen candidates now in clinical trials—targeting complex, late-stage cancers with precision.
How is technology reshaping scalability and access?
By technology, recombinant vaccines held the largest share in 2023, thanks to their scalability, cost-effectiveness, and multi-antigen targeting capabilities. These attributes allow rapid integration into established manufacturing processes, accelerating time-to-market—a decisive advantage for companies aiming to capture early market share.
Which indications are driving adoption?
Cervical …